Literature DB >> 33905020

Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated.

Maria Cristina Leonardi1, Ida Rosalia Scognamiglio2, Barbara Alicja Jereczek-Fossa1,3, Giovanni Corso4,3, Patrick Maisonneuve5, Samantha Dicuonzo6, Damaris Patricia Rojas1, Maria Alessia Zerella1, Anna Morra1, Marianna Alessandra Gerardi1, Mattia Zaffaroni1, Alessandra De Scalzi4, Antonia Girardi4, Francesca Magnoni4, Emilia Montagna7, Cristiana Iuliana Fodor1, Viviana Enrica Galimberti4, Paolo Veronesi4,3, Roberto Orecchia8, Roberto Pacelli2.   

Abstract

PURPOSE: To assess outcome of breast cancer (BC) stages pT1-2 N0-1 after mastectomy alone and to identify prognostic factors calling for the need of postmastectomy radiotherapy.
METHODS: Patients who were not eligible for breast conserving surgery (BCS) were operated on with mastectomy between 1998 and 2008. Locoregional (LRR), distant (DM) control and breast cancer specific survival (BCSS) were retrospectively evaluated. Cumulative incidence (CI) of events was estimated according to Kalbfleisch and Prentice while Gray's test tested difference. Kaplan-Meier method for survival and Cox proportional hazards model for univariable and multivariable analysis were used. A matched pair analysis between mastectomy alone and BCS plus whole breast irradiation (WBI), using the propensity score method, was performed.
RESULTS: 1281 pT1-2 N0 and 1081 pT1-2 N1 were identified. Median follow-up was 8.2 years (9.2 years for survival). Overall, LRR rate was low for both N0 and N1 subgroups (10-year CI, 8.8% and 10.9%, respectively). Young age, lymphovascular invasion and Ki-67 ≥ 20% were proved to be statistically significant prognostic factors at multivariable analysis. The combination of ≥ 2 risk factors increased LRR rate to ≥ 15%. Risk factors combination weighed on LRR rate more than nodal status itself. DM rate doubled moving from negative to positive nodal status (10-year CI 10.5% versus 20.3%, respectively). BCSS remained high in both N0 and N1 subgroups (10-year CI 92.4% versus 84.5%, respectively). Remarkably, all the molecular subtypes except Luminal A significantly affected DM and BCSS both in the N0 and N1 subgroups. Nodes number significantly impacted on DM and BCSS but not on locoregional control. In the matched pair analysis, WBI decreased nodal recurrence rate and improved distant control, without affecting survival.
CONCLUSIONS: Selected patients, namely those with at least two additional risk factors, presented high enough LRR risk to support the use of postmastectomy radiotherapy in both N0 and N1 subgroups. Moreover, the observation that radiotherapy may provide benefits that go beyond local control deserves to be further investigated.

Entities:  

Keywords:  Breast cancer; Intermediate stage; Mastectomy; Radiotherapy; Risk factor

Year:  2021        PMID: 33905020     DOI: 10.1007/s10549-021-06227-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  50 in total

1.  Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.

Authors:  Rita Abi-Raad; Rimoun Boutrus; Rui Wang; Andrzej Niemierko; Shannon Macdonald; Barbara Smith; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-21       Impact factor: 7.038

2.  Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.

Authors:  Xingxing Chen; Xiaoli Yu; Jiayi Chen; Zhen Zhang; Jeffrey Tuan; Zhimin Shao; Xiaomao Guo; Yan Feng
Journal:  Cancer       Date:  2013-04-10       Impact factor: 6.860

3.  Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : An individual patient data analysis of three clinical trials.

Authors:  Omar Abdel-Rahman
Journal:  Strahlenther Onkol       Date:  2018-08-01       Impact factor: 3.621

4.  Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.

Authors:  János Fodor; Csaba Polgár; Tibor Major; György Németh
Journal:  Strahlenther Onkol       Date:  2003-03       Impact factor: 3.621

5.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Authors:  Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

6.  Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.

Authors:  A Katz; E A Strom; T A Buchholz; H D Thames; C D Smith; A Jhingran; G Hortobagyi; A U Buzdar; R Theriault; S E Singletary; M D McNeese
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials.

Authors:  Marie Overgaard; Hanne M Nielsen; Jens Overgaard
Journal:  Radiother Oncol       Date:  2007-02-15       Impact factor: 6.280

Review 8.  Review of Factors Influencing Women's Choice of Mastectomy Versus Breast Conserving Therapy in Early Stage Breast Cancer: A Systematic Review.

Authors:  Jeffrey Gu; Gary Groot; Catherine Boden; Angela Busch; Lorraine Holtslander; Hyun Lim
Journal:  Clin Breast Cancer       Date:  2018-01-03       Impact factor: 3.225

9.  High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c.

Authors:  Marianne Kyndi; Marie Overgaard; Hanne M Nielsen; Flemming B Sørensen; Helle Knudsen; Jens Overgaard
Journal:  Radiother Oncol       Date:  2008-05-28       Impact factor: 6.280

10.  Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment.

Authors:  Andrew McBride; Pamela Allen; Wendy Woodward; Michelle Kim; Henry M Kuerer; Eva Katherine Drinka; Aysegul Sahin; Eric A Strom; Aman Buzdar; Vicente Valero; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-07       Impact factor: 7.038

View more
  2 in total

1.  A propensity score-matched analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy in breast cancer.

Authors:  Francesca Magnoni; Giovanni Corso; Patrick Maisonneuve; Giulia Massari; Luca Alberti; Giulia Castelnovo; Maria Cristina Leonardi; Virgilio Sacchini; Viviana Galimberti; Paolo Veronesi
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-07       Impact factor: 4.553

2.  Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database.

Authors:  Junzhao Wu; Minhao Lv; Peng Yuan; Youzhao Ma; Peiqi Tian; Lianfang Li; Chengzheng Wang; Zhenduo Lu; Min Yan; Xiuchun Chen; Zhenzhen Liu
Journal:  Gland Surg       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.